: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials
: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications
The authors argue that because the drug is highly effective but often hard to tolerate, the medical community should focus on:
: For those who stopped the medication, the median time until they did so was only 7 months .